Mirion Technologies(MIR) - 2025 Q1 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported $29 million of adjusted free cash flow, representing a 62% conversion of adjusted EBITDA [6] - First quarter orders grew by 11.5%, primarily driven by nuclear power orders, marking the best first quarter performance since going public [6][10] - Adjusted EBITDA totaled$ 47 million, an 18.2% increase year-over-year, with margins improving by 260 basis points to 23.1% [8][23] - Adjusted EPS increased by 67% to $0.10 per share compared to$ 0.06 in Q1 2024 [9][24] Business Line Data and Key Metrics Changes - Organic revenue grew by 6% year-over-year, with significant contributions from the nuclear power end market [8][22] - The Nuclear Safety segment saw first quarter revenue of $133.4 million, a 6% increase, with organic revenue up 7.6% [24] - The Medical segment reported first quarter revenue of$ 68.6 million, a 2.7% increase, with organic revenue growth of 3% [27][29] Market Data and Key Metrics Changes - The nuclear power market is expected to see high single-digit growth for the full year, driven by the existing installed base [25][70] - The company noted that 79% of the year-over-year nuclear power order growth came from the existing nuclear fleet [15][66] - The 2024 National Nuclear Energy Public Opinion Survey indicated that over 75% of Americans support the use of nuclear energy, reflecting growing public and political support [12] Company Strategy and Development Direction - The company aims for adjusted EBITDA margins of 30% by 2028, supported by operating leverage and procurement savings [8][15] - The acquisition of OncoSpace, a cloud-native data analytics platform, is expected to enhance the company's cancer care portfolio and go-to-market strategy [6][7] - The company is maintaining a disciplined approach to M&A activity amid uncertain market dynamics [7][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the prospects for large one-time opportunities in the pipeline, estimated at $300 to$ 400 million [10][20] - The company is well-positioned to navigate the current economic environment, with over 70% of revenue being recurring or repeat in nature [14][19] - Management reaffirmed full-year guidance for organic revenue growth, adjusted EBITDA, adjusted EPS, and adjusted free cash flow [20][32] Other Important Information - The company repurchased 1.2 million shares for $18.6 million as part of its capital deployment strategy [9][31] - The expected tariff exposure for 2025 is estimated to be between$ 3 million tailwind and $8 million headwind, with mitigating actions in place [19][20] Q&A Session Summary Question: Can you elaborate on the situation in China regarding tariffs? - Management indicated that most exposure comes from medical equipment produced in the U.S. and that there is potential for some products to be exempt from retaliatory tariffs [38] Question: What is the timeline for the$ 300 to $400 million pipeline? - Management expects a majority of contracts to be awarded within 2025, with projects being larger than typical flow business [47] Question: How is the company positioned regarding pricing power? - Management believes that competitive advantages may strengthen due to anticipated long-term tariff scenarios, potentially enhancing pricing power [78]